Melanoma patient characteristics of the OS cohort
| (n = 104) | |
|---|---|
| Clinical characteristics | |
| Gender, n (%) | |
| Male | 75 (72.1) |
| Female | 29 (27.9) |
| Age, n (range) | |
| Median | 74.5 (22–96) |
| Location of tumor, n (%) | |
| Trunk | 61 (58.7) |
| Extremity | 41 (39.4) |
| Unknown | 2 (1.9) |
| Stage, n (%) | |
| II | 91 (87.5) |
| III | 13 (12.5) |
| Pathologic characteristics | |
| Depth (mm) | |
| Median, n (range) | 2.5 (0.6–26) |
| Ulceration, n (%) | |
| Absent | 36 (34.6) |
| Present | 65 (62.5) |
| Unknown | 3 (2.9) |
| TILs, n (%) | |
| Absent | 2 (1.9) |
| Non-brisk | 59 (56.8) |
| Brisk | 33 (31.7) |
| Unknown | 10 (9.6) |
| Outcome characteristics | |
| Patient follow-up (months) | |
| Median, n (range) | 45 (4–173) |
| OS (months) | |
| Alive (at least 2 years), n (%) | 31 (29.8) |
| Dead, n (%) | 73 (70.2) |
| DSS (months) | |
| Alive or NED at death, n (%) | 42 (40.4) |
| Dead with melanoma, n (%) | 22 (21.2) |
| Unknown, n (%) | 40 (38.4) |
Abbreviations: DSS, disease-specific survival; NED, no evidence of disease; TILs, tumor-infiltrating lymphocytes.